Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection (Q37780903)

23 August 2017

Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection (English)

1 reference

23 August 2017

0 references

Thomas Jacobsen

1

1 reference

PubMed ID

20720240

23 August 2017

Nicole Sifontis

series ordinal

2

1 reference

23 August 2017

1 September 2010

1 reference

American Journal of Health-System Pharmacy

23 August 2017

1 reference

23 August 2017

67

1 reference

23 August 2017

17

1 reference

23 August 2017

1417-1425

1 reference

Novel therapies for cytomegalovirus disease

23 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Maribavir: a novel antiviral agent with activity against cytomegalovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Diagnosis of and screening for cytomegalovirus infection in pregnant women.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Seroprevalence of cytomegalovirus infection in the United States, 1988-1994

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Latent and persistent infections of monocytes and macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Suspected adverse drug events requiring emergency department visits or hospital admissions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Drug-Related Morbidity and Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Scientific perspectives on drug transporters and their role in drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Drug interactions that matter. A critical reappraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

The history of cytomegalovirus and its diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

The case for cytomegalovirus prophylaxis in solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Assessment of potential drug-drug interactions with a prescription claims database

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Drug-associated disease: cytochrome P450 interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Effects of probenecid on ketoprofen kinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Enhancement of Heparin Effect by Probenecid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Prolongation and enhancement of serum methotrexate concentrations by probenecid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Concurrent antiviral and immunosuppressive activities of leflunomide in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Experiences with leflunomide in solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Leflunomide and warfarin interaction: case report and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

Update on immunizations in solid organ transplant recipients: what clinicians need to know

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090424

31 March 2020

Identifiers

DOI

10.2146/AJHP090424

1 reference

23 August 2017

1 reference

PubMed ID

20720240